Cargando…

Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy

BACKGROUND: To establish a prediction model in selecting fit patients with resected pIIIA-N2 non-small cell lung cancer (NSCLC) for postoperative radiotherapy (PORT), and evaluate the model in clinical practice. METHODS: Between January 2003 and December 2005, 221 patients with resected pIIIA-N2 NSC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hui, Zhouguang, Dai, Honghai, Liang, Jun, Lv, Jima, Zhou, Zongmei, Feng, Qinfu, Xiao, Zefen, Chen, Dongfu, Zhang, Hongxing, Yin, Weibo, Wang, Luhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4448386/ https://www.ncbi.nlm.nih.gov/pubmed/26273382 http://dx.doi.org/10.1111/1759-7714.12186

Ejemplares similares

Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer
por: Ding, Xiao, et al.
Publicado: (2012)

Postoperative radiotherapy for completely resected Masaoka stage III thymoma: a retrospective study of 65 cases from a single institution
por: Fan, Chengcheng, et al.
Publicado: (2013)

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial
por: Hui, Zhouguang, et al.
Publicado: (2021)

Postoperative radiotherapy for pathological stage IIIA‐N2 non‐small cell lung cancer with positive surgical margins
por: Yuan, Meng, et al.
Publicado: (2020)

Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy
por: Wang, Wenhui, et al.
Publicado: (2019)

Efficacy of intensity-modulated radiotherapy for resected thoracic esophageal squamous cell carcinoma
por: Zhang, Wencheng, et al.
Publicado: (2015)

The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC)
por: Men, Yu, et al.
Publicado: (2017)

Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases
por: Men, Yu, et al.
Publicado: (2016)

Severe radiation-induced lymphopenia during postoperative radiotherapy or chemoradiotherapy has poor prognosis in patients with stage IIB-III after radical esophagectomy: A post hoc analysis of a randomized controlled trial
por: Ni, Wenjie, et al.
Publicado: (2022)

Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution
por: Wang, Jianyang, et al.
Publicado: (2015)

A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis
por: Sun, Shuang, et al.
Publicado: (2021)

Increased CYFRA 21-1, CEA and NSE are Prognostic of Poor Outcome for Locally Advanced Squamous Cell Carcinoma in Lung: A Nomogram and Recursive Partitioning Risk Stratification Analysis()()()
por: Wang, Jingbo, et al.
Publicado: (2018)

Intensity modulated radiotherapy might be effective for locally advanced esophageal carcinosarcoma: A single center’s experience and review of literature
por: Yang, Siran, et al.
Publicado: (2022)

Clinical outcomes and radiation pneumonitis after concurrent EGFR‐tyrosine kinase inhibitors and radiotherapy for unresectable stage III non‐small cell lung cancer
por: Xu, Kunpeng, et al.
Publicado: (2021)

Radical thoracic radiotherapy may provide favorable outcomes for stage IV non‐small cell lung cancer
por: Wang, Jingbo, et al.
Publicado: (2015)

Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study
por: Wang, Daquan, et al.
Publicado: (2019)

The impact of age on the survival outcomes and risk of radiation pneumonitis in patients with unresectable locally advanced non-small cell lung cancer receiving chemoradiotherapy
por: Zhang, Tao, et al.
Publicado: (2020)

Treatment outcomes of patients with stage III non–small cell lung cancer and interstitial lung diseases receiving intensity‐modulated radiation therapy: A single‐center experience of 85 cases
por: Wu, Linfang, et al.
Publicado: (2022)

Development and validation of a prediction model using molecular marker for long‐term survival in unresectable stage III non‐small cell lung cancer treated with chemoradiotherapy
por: Yang, Yufan, et al.
Publicado: (2021)

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial
por: Bi, Nan, et al.
Publicado: (2020)

Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy
por: Chang, Xiao, et al.
Publicado: (2021)

A Single Center Analysis of Thymic Neuroendocrine Tumors †
por: Zhai, Yirui, et al.
Publicado: (2022)

Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer
por: Lu, Xiaotong, et al.
Publicado: (2022)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non–Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial
por: Bi, Nan, et al.
Publicado: (2019)

Patterns of recurrence after surgery and efficacy of salvage therapy after recurrence in patients with thoracic esophageal squamous cell carcinoma
por: Ni, Wenjie, et al.
Publicado: (2020)

A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma
por: Ni, Wenjie, et al.
Publicado: (2020)

Concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma in the era of intensity modulated radiotherapy: a propensity score‐matched analysis
por: Li, Chen, et al.
Publicado: (2021)

Residual lymph node status is an independent prognostic factor in esophageal squamous cell Carcinoma with pathologic T0 after preoperative radiotherapy
por: Wang, Qifeng, et al.
Publicado: (2015)

Survival benefit of surgery in patients with clinical T4 esophageal cancer who achieved complete or partial response after neoadjuvant chemoradiotherapy or radiotherapy
por: Gao, Lin-Rui, et al.
Publicado: (2022)

Risk factors for locoregional recurrence in patients with resected N1 non-small cell lung cancer: a retrospective study to identify patterns of failure and implications for adjuvant radiotherapy
por: Fan, Chengcheng, et al.
Publicado: (2013)

Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis
por: Li, Chen, et al.
Publicado: (2021)

Real world practice of postoperative radiotherapy for patients with completely resected pIIIA-N2 non-small cell lung cancer: a national survey of radiation oncologists in China
por: Zhou, Shujie, et al.
Publicado: (2023)

Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
por: Liu, Lipin, et al.
Publicado: (2015)

Impact of thoracic radiation therapy after chemotherapy on survival in extensive‐stage small cell lung cancer: A propensity score‐matched analysis
por: Deng, Lei, et al.
Publicado: (2019)

Postoperative Radiotherapy in Completely Resected IIIA-N2 Non-small Cell Lung Cancer: Quit or Not?
por: Chen, Yu, et al.
Publicado: (2023)

Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer
por: Ran, Juntao, et al.
Publicado: (2017)

Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol
por: Chang, Xiao, et al.
Publicado: (2020)

Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment
por: Brascia, Debora, et al.
Publicado: (2020)

A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcinoma: a retrospective analysis
por: Deng, Wei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_td4eku2kvs18t5mq4qgtp0jc19